As previously established, the overexpression of PD-L1 observed in cHL and non-GCB DLBCL is associated with an adverse prognosis in HL and DLBCL patients [9,12,15], suggesting that the PD-1/PD-L1 axis plays a key role in IE strategies for these lymphomas. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.